Expert Insights on Novel NMOSD Treatments : Episode 9
Opinion
Video
Long-term NMOSD Data
Author(s):
Key Takeaways
- Satralizumab and inebilizumab demonstrate sustained efficacy and favorable safety profiles in NMOSD management, reducing relapse rates significantly.
- Satralizumab targets interleukin-6 receptors, while inebilizumab targets CD19, both contributing to reduced relapse rates in NMOSD patients.
Sean Pittock, MD, discusses the long-term efficacy and safety results of other FDA-approved treatments for neuromyelitis optica spectrum disorder, including satralizumab, inebilizumab, and the off-label use of rituximab.
Video content above is prompted by the following:
Can you also comment on long-term efficacy and safety results with other FDA-approved treatments, including satralizumab, inebilizumab, and off-label use of rituximab?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Videos
Related Content
